Pharmacokinetics and tissues distribution of rosiglitazone in rats

ZHANG Ling-hong; DUAN Ya-le; LI Yu-bo; WAN Xue-mei; ZHAO Zheng

Issue 4

Nov. 2011

Turn off MathJax

Article Contents

Article Navigation > Journal of East China Normal University (Natural Sciences) > 2011 > (4): 104-114

ZHANG Ling-hong, DUAN Ya-le, LI Yu-bo, WAN Xue-mei, ZHAO Zheng. Pharmacokinetics and tissues distribution of rosiglitazone in rats[J]. Journal of East China Normal University (Natural Sciences), 2011, (4): 104-114.

Citation:

ZHANG Ling-hong, DUAN Ya-le, LI Yu-bo, WAN Xue-mei, ZHAO Zheng. Pharmacokinetics and tissues distribution of rosiglitazone in rats[J]. Journal of East China Normal University (Natural Sciences), 2011, (4): 104-114.

Citation:

PDF( 1055 KB)

Pharmacokinetics and tissues distribution of rosiglitazone in rats

1.
Key Laboratories of MOE and STCSM, Institute of Brain Functional Genomics, East China Normal University， Shanghai 200062, China

Received Date: 2010-05-01
Rev Recd Date: 2010-08-01
Publish Date: 2011-07-05

Abstract

Abstract

A simple, rapid and selective HPLC method was developed and validated to determinate rosiglitazone in rat plasma, tissues and cerebrospinal fluid. Samples were prepared, with a higher extraction recovery (96.72% in plasma， 95.63% in tissues and 90.67% in cerebrospinal fluid), based on a simple methanol protein precipitation. Assay of rosiglitazone was achieved on a reversed-phase C18 column (250 mm 4.6 mm, 5 m) with a mobile phase consisting of acetonitrile and 20 mmol/L ammonium acetate pH 6.0 (53∶47, v/v) at a flow rate of 0.6 mL/min. The method was applied to study pharmacokinetics, distribution of rosiglitazone in rats after a single intragastric administration. The rosiglitazone was rapidly absorbed (Tmax 0.5～1 h) with an elimination half-life of 2.5 hours. The highest levels of the drug were observed in liver and fat while the lowest levels in the brain and spleen. The method was also used for the determination of rosiglitazone in cerebrospinal fluid. The result showed that rosiglitazone can be detected in cerebrospinal fluid, thus providing direct evidence that rosiglitazone can permeate cross blood brain barrier.
- rosiglitazone,
- HPLC-UV,
- pharmacokinetics,
- tissues distribution,
- cerebrospinal fluid

FullText(HTML)

References(1)

References

[1]

［1］ DAY C. Thiazolidinediones: a new class of antidiabetic drugs［J］. Diabet Med, 1999, 16(3): 179-192.

［2］ TONTONOZ P, HU E, SPIEGELMAN B M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma［J］. Curr Opin Genet Dev, 1995, 5(5): 571-576.

［3］ ELDERSHAW T P, RATTIGAN S, CAWTHORNE M A, et al. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb［J］. Horm Metab Res, 1995, 27(4): 169-172.

［4］ WATSON G S, CHOLERTON B A, REGER M A, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study［J］. Am J Geriat Psychiat, 2005, 13(11): 950-958.

［5］ RISNER M E, SAUNDERS A M, ALTMAN J F, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease［J］. Pharmacogenomics J, 2006, 6(4): 246-254.

［6］ ESCRIBANO L, SIMON A M, PEREZ-MEDIAVILLA A, et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model［J］. Biochem Biophys Res Commun, 2009, 379(2): 406-410.

［7］ PEDERSEN W A, MCMILLAN P J, KULSTAD J J, et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice［J］. Exp Neurol, 2006, 199(2): 265-273.

［8］ XUE B, KAHN B B. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues［J］. J Physiol, 2006, 574(Pt 1): 73-83.

［9］ KIM M S, LEE K U. Role of hypothalamic 5′-AMP-activated protein kinase in the regulation of food intake and energy homeostasis［J］. J Mol Med, 2005, 83(7): 514-520.

［10］ FRYER L G, PARBU-PATEL A, CARLING D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways［J］. J Biol Chem, 2002, 277(28): 25226-25232.

［11］ TURNLEY A M, STAPLETON D, MANN R J, et al. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system［J］. J Neurochem, 1999, 72(4): 1707-1716.

［12］ FESTUCCIA W T, OZTEZCAN S, LAPLANTE M, et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status［J］. Endocrinology, 2008, 149(5): 2121-2130.

［13］ LANDRETH G. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease［J］. Exp Neurol, 2006, 199(2): 245-248.

［14］ KANG X, WANG F, XIE Z, et al. A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877(7): 645-648.

［15］ KOLTE B L, RAUT B B, DEO A A, et al. Liquid chromatographic method for the determination of rosiglitazone in human plasma［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 788(1): 37-44.

［16］ MUXLOW A M, FOWLES S, RUSSELL P. Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma［J］. J Chromatogr B Biomed Sci Appl, 2001, 752(1): 77-84.

［17］ NIROGI R, KANDIKERE V, MUDIGONDA K, et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system［J］. J Neurosci Methods, 2009, 178(1): 116-119.

［18］ LAI Y L, SMITH P M, LAMM W J, et al. Sampling and analysis of cerebrospinal fluid for chronic studies in awake rats［J］. J Appl Physiol,1983, 54(6): 1754-1757.

［19］ HRUSKA M W, FRYE R F. Simplified method for determination of rosiglitazone in human plasma［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 803(2): 317-320.

［20］ ZHANG L, TIAN Y, ZHANG Z, et al. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 854(1-2): 91-98.

［21］ FREED M I, ALLEN A, JORKASKY D K, et al. Systemic exposure to rosiglitazone is unaltered by food［J］. Eur J Clin Pharmacol, 1999, 55(1): 53-56.

［22］ COX P J, RYAN D A, HOLLIS F J, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans［J］. Drug Metab Dispos, 2000, 28(7): 772-780.

［23］ BALDWIN S J, CLARKE S E, CHENERY R J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone［J］. Br J Clin Pharmacol, 1999, 48(3): 424-432.

［24］ SARRUF D A, YU F, NGUYEN H T, et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis［J］. Endocrinology, 2009, 150(2): 707-712.

Relative Articles

Supplements(0)

Cited By

Proportional views